Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 25 (September 1), 2007: pp. 3930-3935
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.5022

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scartozzi, M.
Right arrow Articles by Cascinu, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scartozzi, M.
Right arrow Articles by Cascinu, S.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

Mario Scartozzi, Italo Bearzi, Chiara Pierantoni, Alessandra Mandolesi, Fotios Loupakis, Alberto Zaniboni, Vincenzo Catalano, Antonello Quadri, Fausto Zorzi, Rossana Berardi, Tommasina Biscotti, Roberto Labianca, Alfredo Falcone, Stefano Cascinu

From the Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti-Università Politecnica delle Marche, Ancona; Oncologia Medica, Ospedale Civico, Livorno - Università degli Studi di Pisa, Pisa; Oncologia Medica and Anatomia Patologica Casa di Cura Poliambulanza, Brescia; Oncologia Medica, AO San Salvatore, Pesaro; and Oncologia Medica, Ospedali Riuniti, Bergamo, Italy

Address reprint requests to Stefano Cascinu, MD, Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy; e-mail: cascinu{at}yahoo.com

Purpose NF-kB expression has been shown to be responsible for resistance to antineoplastic agents and it also plays a part in the activation of the epidermal growth factor receptor downstream signaling pathway in colorectal tumors. The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan.

Patients and Methods We analyzed retrospectively the immunoreactivity for NF-kB in irinotecan-refractory patients receiving cetuximab and irinotecan.

Results Seventy-six patients were analyzed. Cetuximab and irinotecan were administered as second-line chemotherapy in 19 patients and after ≥ two lines of chemotherapy in the remaining 57 patients. We observed a partial response (PR) in 16 patients for an overall response rate of 24%. Thirty-two patients (48%) experienced progressive disease; median time to progression (TTP) was 3.6 months and median overall survival was 10.3 months. NF-kB was positive in 46 patients (60%). All main clinical characteristics were well balanced between NF-kB–positive and NF-kB–negative patients. The response rate was 10% (four PRs) versus 48% (12 PRs; P = .0007) in NF-kB–positive and NF-kB–negative tumors, respectively. Median TTP in NF-kB–positive patients was 3 v 6.4 months in the remaining patients (P = .021). Median overall survival was 9.5 v 15.8 months for NF-kB–positive and NF-kB–negative patients, respectively (P = .036)

Conclusion The difference in median TTP, overall survival, and response rate seem to confirm that NF-kB may play a crucial role in predicting the efficacy of cetuximab and irinotecan in advanced colorectal tumors.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Activated NF-kB in Colorectal Cancer: Predictive or Prognostic Factor?
    Giovanni Brandi, Maria A. Pantaleo, Guido Biasco, and Paola Paterini
    JCO 2008 26: 1388-1389 [Full Text]


This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
X. Liu, B. Wang, X. Ma, and Y. Guo
NF-{kappa}B Activation Through the Alternative Pathway Correlates with Chemoresistance and Poor Survival in Extranodal NK/T-cell Lymphoma, Nasal Type
Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 418 - 424.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Ogino, K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, A. T. Chan, J. A. Engelman, P. Kraft, L. C. Cantley, et al.
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
J. Clin. Oncol., March 20, 2009; 27(9): 1477 - 1484.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Bibeau, E. Lopez-Crapez, F. Di Fiore, S. Thezenas, M. Ychou, F. Blanchard, A. Lamy, F. Penault-Llorca, T. Frebourg, P. Michel, et al.
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
J. Clin. Oncol., March 1, 2009; 27(7): 1122 - 1129.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al.
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Ann. Onc., February 1, 2009; 20(2): 213 - 226.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Ogino, K. Nosho, J. A. Meyerhardt, G. J. Kirkner, A. T. Chan, T. Kawasaki, E. L. Giovannucci, M. Loda, and C. S. Fuchs
Cohort Study of Fatty Acid Synthase Expression and Patient Survival in Colon Cancer
J. Clin. Oncol., December 10, 2008; 26(35): 5713 - 5720.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Wang, M. S. Veena, K. Stevenson, C. Tang, B. Ho, J. D. Suh, V. M. Duarte, K. F. Faull, K. Mehta, E. S. Srivatsan, et al.
Liposome-Encapsulated Curcumin Suppresses Growth of Head and Neck Squamous Cell Carcinoma In vitro and in Xenografts through the Inhibition of Nuclear Factor {kappa}B by an AKT-Independent Pathway
Clin. Cancer Res., October 1, 2008; 14(19): 6228 - 6236.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Vincenzi, D. Santini, S. Galluzzo, A. Russo, F. Fulfaro, M. Silletta, F. Battistoni, L. Rocci, B. B. Zobel, V. Adamo, et al.
Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome
Clin. Cancer Res., July 1, 2008; 14(13): 4219 - 4224.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz
Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study
J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Brandi, M. A. Pantaleo, G. Biasco, and P. Paterini
Activated NF-kB in Colorectal Cancer: Predictive or Prognostic Factor?
J. Clin. Oncol., March 10, 2008; 26(8): 1388 - 1389.
[Full Text] [PDF]


Home page
JCOHome page
M. Scartozzi, R. Berardi, S. Cascinu, I. Bearzi, and A. Mandolesi
In Reply:
J. Clin. Oncol., March 10, 2008; 26(8): 1389 - 1390.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online